Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance | MicrobiomeTrials
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-14Est. Completion: 2027-06-15
Enrollment target: 52 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States